| Summary of royalty and commercial payment receivable activities |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the nine months ended September 30, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Acquisition of Royalty and Commercial Payment Receivables |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Recognition of Contingent Consideration |
|
|
Impairment of Royalty and Commercial Payment Receivables |
|
|
Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method |
|
|
Balance as of September 30, 2024 |
Daré |
|
$ |
— |
|
$ |
22,000 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
22,000 |
Talphera |
|
|
— |
|
|
8,000 |
|
|
(80) |
|
|
— |
|
|
— |
|
|
— |
|
|
7,920 |
LadRx |
|
|
6,000 |
|
|
— |
|
|
— |
|
|
1,000 |
|
|
— |
|
|
— |
|
|
7,000 |
Aptevo |
|
|
7,976 |
|
|
— |
|
|
(794) |
|
|
— |
|
|
— |
|
|
— |
|
|
7,182 |
Agenus |
|
|
14,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
(14,000) |
|
|
— |
|
|
— |
Aronora |
|
|
9,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
(9,000) |
|
|
— |
|
|
— |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
10,000 |
Viracta |
|
|
8,500 |
|
|
— |
|
|
(8,500) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Kuros |
|
|
4,500 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
4,500 |
Affitech |
|
|
12,191 |
|
|
— |
|
|
(7,396) |
|
|
3,000 |
|
|
— |
|
|
(7,795) |
|
|
— |
Total |
|
$ |
72,167 |
|
$ |
30,000 |
|
$ |
(16,770) |
|
$ |
4,000 |
|
$ |
(23,000) |
|
$ |
(7,795) |
|
$ |
58,602 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the nine months ended September 30, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method |
|
|
Income from Purchased Receivables Under EIR Method |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Balance as of September 30, 2024 |
Affitech |
|
$ |
— |
|
$ |
7,795 |
|
$ |
9,985 |
|
$ |
(9,493) |
|
$ |
8,287 |
Total |
|
$ |
— |
|
$ |
7,795 |
|
$ |
9,985 |
|
$ |
(9,493) |
|
$ |
8,287 |
|